{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:44:51Z","timestamp":1783723491248,"version":"3.55.0"},"reference-count":175,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020970","name":"Rashtriya Uchchatar Shiksha Abhiyan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020970","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004541","name":"Ministry of Education, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jconrel.2021.09.020","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T06:26:14Z","timestamp":1632464774000},"page":"51-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Road map to the treatment of neglected tropical diseases: Nanocarriers interventions"],"prefix":"10.1016","volume":"339","author":[{"given":"Garima","family":"Joshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheikh Shahnawaz","family":"Quadir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khushwant S.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9324","key":"10.1016\/j.jconrel.2021.09.020_bb0005","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/S0140-6736(02)09096-7","article-title":"Drug development for neglected diseases: a deficient market and a public-health policy failure","volume":"359","author":"Trouiller","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0010","first-page":"14","article-title":"Neglected tropical diseases","volume":"3","author":"Bhattacharya","year":"2018","journal-title":"KJ Gastro OA"},{"issue":"6","key":"10.1016\/j.jconrel.2021.09.020_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002162","article-title":"The need for full integration of snakebite envenoming within a global Strategy to combat the neglected Tropical diseases: The way forward","volume":"7","author":"Guti\u00e9rrez","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0020","series-title":"Removing Obstacles to Healthy Development: Report on Infectious Diseases","author":"World Health Organization","year":"1999"},{"issue":"9","key":"10.1016\/j.jconrel.2021.09.020_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020302","article-title":"A breakthrough in R&D for neglected diseases: new ways to get the drugs we need","volume":"2","author":"Moran","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0030","series-title":"Department of Public Information. Millennium Development Goals Report 2009 (Includes the 2009 Progress Chart)","author":"United Nations","year":"2009"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0035","first-page":"175","article-title":"Drug discovery and development for neglected diseases: the DNDi model","volume":"5","author":"Chatelain","year":"2011","journal-title":"Drug Des Devel Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2021.09.020_bb0040","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.clinthera.2016.02.031","article-title":"Progress report on neglected tropical disease drug donation programs","volume":"38","author":"Cohen","year":"2016","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0045","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.actatropica.2017.02.019","article-title":"Nanopharmaceuticals as a solution to neglected diseases: is it possible?","volume":"170","author":"Islan","year":"2017","journal-title":"Acta Trop."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0050","series-title":"WHO-Department of Control of Neglected Tropical Diseases. A Road Map for Neglected Tropical Diseases 2021\u20132030, Ending the Neglect to Attain the Sustainable Development Goals 2020; WHO\/UCN\/NTD\/2020.01","year":"2020"},{"issue":"21","key":"10.1016\/j.jconrel.2021.09.020_bb0055","doi-asserted-by":"crossref","first-page":"7981","DOI":"10.3390\/ijms21217981","article-title":"Loop-mediated isothermal amplification as point-of-care diagnosis for neglected parasitic infections","volume":"21","author":"Avenda\u00f1o","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0060","series-title":"Investing to Overcome the Global Impact of Neglected Tropical Diseases: Third WHO Report on Neglected Tropical Diseases 2015","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0065","series-title":"Working to Overcome the Global Impact of Neglected Tropical Diseases: first WHO Report on Neglected Tropical Diseases","author":"World Health Organization","year":"2010"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0070","series-title":"Will COVID-19 Become the Next Neglected Tropical Disease?","author":"Hotez","year":"2021"},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40249-020-0630-9","article-title":"Neglected tropical diseases: an effective global response to local poverty-related disease priorities","volume":"9","author":"Engels","year":"2020","journal-title":"Infect. Dis. Poverty."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0080","series-title":"WHO-Department of Control of Neglected Tropical Diseases. A Road Map for Neglected Tropical Diseases 2021\u20132030, Ending the Neglect to Attain the Sustainable Development Goals 2020; WHO\/ UCN\/NTD\/2020.01","year":"2020"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0085","series-title":"Mental Health of People With Neglected Tropical Diseases: Towards a Person-centred Approach","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0090","series-title":"International Health","article-title":"Increasing efficiencies from integrating control and elimination programmes for soil-transmitted helminths and schistosomiasis","author":"Rollinson","year":"2021"},{"issue":"2","key":"10.1016\/j.jconrel.2021.09.020_bb0095","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/trstmh\/traa132","article-title":"Lessons from the field: integrated survey methodologies for neglected tropical diseases","volume":"115","author":"Harding-Esch","year":"2021","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"3","key":"10.1016\/j.jconrel.2021.09.020_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008106","article-title":"The safety of combined triple drug therapy with ivermectin, diethylcarbamazine and albendazole in the neglected tropical diseases co-endemic setting of Fiji: a cluster randomised trial","volume":"14","author":"Hardy","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"10","key":"10.1016\/j.jconrel.2021.09.020_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008837","article-title":"Core components, concepts and strategies for parasitic and vector-borne disease elimination with a focus on schistosomiasis: a landscape analysis","volume":"14","author":"Monnier","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0110","series-title":"A Road Map for Neglected Tropical Diseases 2021\u20132030","author":"Malecela","year":"2021"},{"issue":"4","key":"10.1016\/j.jconrel.2021.09.020_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008240","article-title":"Mycetoma in Uganda: a neglected tropical disease","volume":"14","author":"Kwizera","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"12","key":"10.1016\/j.jconrel.2021.09.020_bb0120","doi-asserted-by":"crossref","DOI":"10.2196\/22478","article-title":"Mobile health strategies to tackle skin neglected Tropical diseases with recommendations from innovative experiences: systematic review","volume":"8","author":"Carrion","year":"2020","journal-title":"JMIR mHealth uHealth."},{"issue":"2","key":"10.1016\/j.jconrel.2021.09.020_bb0125","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/trstmh\/traa114","article-title":"Towards a comprehensive research and development plan to support the control, elimination and eradication of neglected tropical diseases","volume":"115","author":"Mabey","year":"2021","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0130","series-title":"Ending the Neglect to Attain the Sustainable Development Goals: A Framework for Monitoring and Evaluating Progress of the Road Map for Neglected Tropical Diseases 2021\u20132030","author":"World Health Organization","year":"2021"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0135","series-title":"How Many Neglected Tropical Diseases can we Eliminate by 2030? RSTMH Presidential Address","author":"Mabey","year":"2021"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0140","unstructured":"The, E., To, N., Sustainable, A. T. H. E., Goals, D., Strategy, A. G., Water, O. N., To, H., & Tropical, C. N. (n.d.). 2021\u20132030."},{"issue":"2","key":"10.1016\/j.jconrel.2021.09.020_bb0145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/trstmh\/trab001","article-title":"Building on a decade of progress in water, sanitation and hygiene to control, eliminate and eradicate neglected tropical diseases","volume":"115","author":"Boisson","year":"2021","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0150","doi-asserted-by":"crossref","unstructured":"Pedrique, Belen et al. The drug and vaccine landscape for neglected diseases (2000\u221211): a systematic assessment. Lancet Glob. Health, 1, 6, e371 - e379.","DOI":"10.1016\/S2214-109X(13)70078-0"},{"issue":"S1","key":"10.1016\/j.jconrel.2021.09.020_bb0155","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1038\/sj.embor.embor851","article-title":"Neglected diseases: under-funded research and inadequate health interventions","volume":"4","author":"Morel","year":"2003","journal-title":"EMBO Rep."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0160","doi-asserted-by":"crossref","unstructured":"de Oliveira SK, Chiaradia-Delatorre LD, Mascarello A, Veleirinho B, Ramlov F, Kuhnen S, Yunes RA, Maraschin M. From Bench to Bedside: Natural Products and Analogs for the Treatment of Neglected Tropical Diseases (NTDs). In Studies in Natural Products Chemistry. 2015 Jan 1 (Vol. 44, pp. 33-92). Elsevier.","DOI":"10.1016\/B978-0-444-63460-3.00002-X"},{"issue":"41","key":"10.1016\/j.jconrel.2021.09.020_bb0165","doi-asserted-by":"crossref","first-page":"7316","DOI":"10.2174\/138161281941131219135458","article-title":"Nanotechnological strategies for the treatment of neglected diseases","volume":"19","author":"Khalil","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0170","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/9781119711698.ch18","article-title":"Role of nanomedicines in neglected tropical diseases","author":"Shukla","year":"2021","journal-title":"Nanopharm. Adv. Deliv. Syst."},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003379","article-title":"A changing model for developing health products for poverty-related infectious diseases","volume":"9","author":"Olliaro","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0180","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/9781119711698.ch18","article-title":"Role of nanomedicines in neglected tropical diseases","volume":"12","author":"Shukla","year":"2021","journal-title":"Nanopharma. Adv. Deliv. Syst."},{"issue":"44","key":"10.1016\/j.jconrel.2021.09.020_bb0185","article-title":"Technological prospecting: the nanotechnology applied to neglected diseases","volume":"39","author":"Silva","year":"2018","journal-title":"Revista ESPACIOS."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0190","series-title":"Nanopharmaceutical Advanced Delivery Systems","author":"Dave","year":"2020"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0195","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/9781119711698.ch18","article-title":"Role of nanomedicines in neglected tropical diseases","volume":"12","author":"Shukla","year":"2021","journal-title":"Nanopharma. Adv. Deliv. Syst."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0200","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/0024-3205(87)90005-1","article-title":"Trypanocidal activity of the stearylamine -bearing liposome","volume":"40","author":"Yoshihara","year":"1987","journal-title":"Life Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2021.09.020_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006793","article-title":"Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype","volume":"12","author":"Metz","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0210","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/9781119711698.ch18","article-title":"Role of nanomedicines in neglected tropical diseases","volume":"12","author":"Shukla","year":"2021","journal-title":"Nanopharma. Adv. Deliv. Syst."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0215","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2014.11.002","article-title":"Nanobody conjugated PLGA nanoparticles for active targeting of African trypanosomiasis","volume":"197","author":"Arias","year":"2015","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2021.09.020_bb0220","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2217\/nnm-2018-0038","article-title":"Mannosylated thiolated paromomycin-loaded PLGA nanoparticles for the oral therapy of visceral leishmaniasis","volume":"14","author":"Afzal","year":"2019","journal-title":"Nanomedicine."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0225","series-title":"Effective Single Drug Treatment of Lymphatic Filariasis through Enhanced Transdermal Delivery of Ivermectin Liposomes using Solid and Dissolving Microneedles","author":"Devineni","year":"2021"},{"issue":"6","key":"10.1016\/j.jconrel.2021.09.020_bb0230","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1021\/acs.molpharmaceut.6b00206","article-title":"Subcutaneously administered ultrafine PLGA nanoparticles containing doxycycline hydrochloride target lymphatic filarial parasites","volume":"13","author":"Singh","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0235","doi-asserted-by":"crossref","first-page":"110823","DOI":"10.1016\/j.colsurfb.2020.110823","article-title":"Development of microemulsion based topical ivermectin formulations: pre-formulation and formulation studies","volume":"189","author":"Das","year":"2020","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0240","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/vim.2017.0024","article-title":"Evaluation of G2 citric acid-based dendrimer as an adjuvant in veterinary rabies vaccine","volume":"31","author":"Asgary","year":"2018","journal-title":"Viral Immunol."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0245","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.2147\/IJN.S109098","article-title":"Green synthesis and evaluation of silver nanoparticles as adjuvant in rabies veterinary vaccine","volume":"11","author":"Asgary","year":"2016","journal-title":"Int. J. Nanomedicine"},{"issue":"11","key":"10.1016\/j.jconrel.2021.09.020_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141788","article-title":"Miltefosine lipid nanocapsules for single dose oral treatment of schistosomiasis mansoni: a preclinical study","volume":"10","author":"Eissa","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jconrel.2021.09.020_bb0255","doi-asserted-by":"crossref","first-page":"508","DOI":"10.37360\/blacpma.20.19.5.35","article-title":"Ocotea pulchella as an alternative against schistosomiasis: chemical analysis, development of nanoemulsion and biological control activity","volume":"19","author":"Passos","year":"2020","journal-title":"Bol. Latinoameric. Caribe Plant. Med. Arom\u00e1t."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0260","doi-asserted-by":"crossref","first-page":"110823","DOI":"10.1016\/j.colsurfb.2020.110823","article-title":"Development of microemulsion based topical ivermectin formulations: pre-formulation and formulation studies","volume":"189","author":"Das","year":"2020","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"10","key":"10.1016\/j.jconrel.2021.09.020_bb0265","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1473-3099(19)30279-8","article-title":"Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial","volume":"19","author":"Abraham","year":"2019","journal-title":"Lancet Infect. Dis."},{"issue":"27","key":"10.1016\/j.jconrel.2021.09.020_bb0270","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1016\/j.biomaterials.2011.05.038","article-title":"Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles","volume":"32","author":"Toti","year":"2011","journal-title":"Biomaterials."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0275","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jconrel.2021.07.003","article-title":"Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy","volume":"336","author":"Yasaswi","year":"2021","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0280","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.nano.2009.04.008","article-title":"Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery","volume":"6","author":"Mishra","year":"2010","journal-title":"Nanomedicine"},{"issue":"6","key":"10.1016\/j.jconrel.2021.09.020_bb0285","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.addr.2007.04.009","article-title":"Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles","volume":"59","author":"Date","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2021.09.020_bb0290","doi-asserted-by":"crossref","first-page":"396","DOI":"10.2174\/157341309789378069","article-title":"State of the art of nanobiotechnology applications in neglected diseases","volume":"5","author":"Duran","year":"2009","journal-title":"Curr. Nanosci."},{"issue":"1\u20133","key":"10.1016\/j.jconrel.2021.09.020_bb0295","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jbiotec.2004.06.007","article-title":"Challenges and solutions for the delivery of biotech drugs\u2013a review of drug nanocrystal technology and lipid nanoparticles","volume":"113","author":"Muller","year":"2004","journal-title":"J. Biotechnol."},{"issue":"10","key":"10.1016\/j.jconrel.2021.09.020_bb0300","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.tibtech.2012.06.004","article-title":"Antibacterial properties of nanoparticles","volume":"30","author":"Hajipour","year":"2012","journal-title":"Trends Biotechnol."},{"issue":"3","key":"10.1016\/j.jconrel.2021.09.020_bb0305","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clindermatol.2008.09.021","article-title":"Buruli ulcer","volume":"27","author":"Portaels","year":"2009","journal-title":"Clin. Dermatol."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0310","series-title":"World Health Organization, Global Buruli Ulcer Initiative. Buruli ulcer: Mycobacterium Ulcerans Infection","author":"Asiedu","year":"2000"},{"issue":"10","key":"10.1016\/j.jconrel.2021.09.020_bb0315","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2217\/fmb.11.101","article-title":"Treating mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?","volume":"6","author":"Converse","year":"2011","journal-title":"Future Microbiol."},{"issue":"4","key":"10.1016\/j.jconrel.2021.09.020_bb0320","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01507-17","article-title":"Buruli ulcer: review of a neglected skin mycobacterial disease","volume":"56","author":"Guarner","year":"2018","journal-title":"J. Clin. Microbiol."},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0325","first-page":"119","article-title":"Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review","volume":"15","author":"Tanywe","year":"2017","journal-title":"JBI Evid. Synth."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0330","series-title":"WHO 2015 Rapid Diagnosis of Buruli Ulcer now Possible at District-level Health Facilities","year":"2015"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0335","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41467-019-08464-y","article-title":"The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model","volume":"10","author":"Liu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0340","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s42003-020-0920-6","article-title":"Genome-wide association study of Buruli ulcer in rural Benin highlights role of two LncRNAs and the autophagy pathway","volume":"3","author":"Manry","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0345","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/0024-3205(80)90268-4","article-title":"Liposomes\u2014A selective drug delivery system for the topical route of administration. 1. Lotion dosage form","volume":"26","author":"Mezei","year":"1980","journal-title":"Life Sci."},{"issue":"43","key":"10.1016\/j.jconrel.2021.09.020_bb0350","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.2174\/1381612822666160701083812","article-title":"Lipid-based nanocarriers for cutaneous Leishmaniais and Buruli ulcer management","volume":"22","author":"Simoes","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"10232","key":"10.1016\/j.jconrel.2021.09.020_bb0355","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0140-6736(20)30047-7","article-title":"Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial","volume":"395","author":"Phillips","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0054856","article-title":"Social support, socio-economic status, health and abuse among older people in seven European countries","volume":"8","author":"Melchiorre","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actatropica.2015.07.018","article-title":"The multiple and complex and changeable scenarios of the Trypanosoma cruzi transmission cycle in the sylvatic environment","volume":"151","author":"Jansen","year":"2015","journal-title":"Acta Trop."},{"issue":"6","key":"10.1016\/j.jconrel.2021.09.020_bb0370","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4155\/fmc.14.17","article-title":"Antimicrobial clay-based materials for wound care","volume":"6","author":"Gaskell","year":"2014","journal-title":"Future Med. Chem."},{"issue":"11","key":"10.1016\/j.jconrel.2021.09.020_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006809","article-title":"The economic value of identifying and treating Chagas disease patients earlier and the impact on Trypanosoma cruzi transmission","volume":"12","author":"Bartsch","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0380","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/0024-3205(87)90005-1","article-title":"Trypanocidal activity of the stearylamine -bearing liposome","volume":"40","author":"Yoshihara","year":"1987","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0385","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.2042-7158.1998.tb03301.x","article-title":"Characterization and trypanocidal activity of nifurtimox-containing andempty nanoparticles of polyethylcyanoacrylates","volume":"50","author":"Gonzalez-Martin","year":"1998","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0390","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0378-5173(02)00453-2","article-title":"Development and invitro characterisation of a benznidazole liposomal formulation","volume":"249","author":"Morilla","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0395","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijpharm.2004.03.025","article-title":"Intravenous liposomal benznidazole as trypanocidal agent: increasing drugdelivery to liver is not enough","volume":"278","author":"Morilla","year":"2004","journal-title":"Int. J. Pharm."},{"issue":"12","key":"10.1016\/j.jconrel.2021.09.020_bb0400","doi-asserted-by":"crossref","first-page":"e0006119","DOI":"10.1371\/journal.pntd.0006119","article-title":"Elucidating the impact of low doses of nano-formulated benznidazole in acute experimental Chagas disease","volume":"11","author":"Rial","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0405","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejps.2018.04.034","article-title":"Multi-kinetic release of benznidazole-loaded multiparticulate drug delivery systems based on polymethacrylate interpolyelectrolyte complexes","volume":"120","author":"Garc\u00eda","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2021.09.020_bb0410","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","article-title":"The current and future global distribution and population at risk of dengue","volume":"4","author":"Messina","year":"2019","journal-title":"Nat. Microbiol."},{"issue":"4","key":"10.1016\/j.jconrel.2021.09.020_bb0415","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.meegid.2009.02.003","article-title":"Molecular evolution of dengue viruses: contributions of phylogenetics to understanding the history and epidemiology of the preeminent arboviral disease","volume":"9","author":"Weaver","year":"2009","journal-title":"Infect. Genet. Evol."},{"issue":"5","key":"10.1016\/j.jconrel.2021.09.020_bb0420","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1128\/CDLI.7.5.856-857.2000","article-title":"Human dengue antibodies against structural and nonstructural proteins","volume":"7","author":"Vald\u00e9s","year":"2000","journal-title":"Clin. Diagn. Lab. Immunol."},{"issue":"2","key":"10.1016\/j.jconrel.2021.09.020_bb0425","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40089-017-0208-0","article-title":"Nanotechnology and nanocarrier-based approaches on treatment of degenerative diseases","volume":"7","author":"Chowdhury","year":"2017","journal-title":"Int. Nano Lett."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0430","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/9781681085623118070004","article-title":"Towards host-cell targeting therapies to treat dengue virus infections","volume":"7","author":"Garc\u00eda","year":"2018","journal-title":"Front. Anti-infect. Drug Discov."},{"issue":"9","key":"10.1016\/j.jconrel.2021.09.020_bb0435","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1007\/s00436-015-4556-2","article-title":"Green-synthesized silver nanoparticles as a novel control tool against dengue virus (DEN-2) and its primary vector Aedes aegypti","volume":"114","author":"Sujitha","year":"2015","journal-title":"Parasitol. Res."},{"issue":"10","key":"10.1016\/j.jconrel.2021.09.020_bb0440","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1007\/s00436-015-4582-0","article-title":"Predation by Asian bullfrog tadpoles, Hoplobatrachustigerinus, against the dengue vector, Aedesaegypti, in an aquatic environment treated with mosquitocidal nanoparticles","volume":"114","author":"Murugan","year":"2015","journal-title":"Parasitol. Res."},{"issue":"9","key":"10.1016\/j.jconrel.2021.09.020_bb0445","doi-asserted-by":"crossref","first-page":"e0006793","DOI":"10.1371\/journal.pntd.0006793","article-title":"Nanoparticle delivery of a tetravalent E protein subunit vaccine induces balanced, type-specific neutralizing antibodies to each dengue virus serotype","volume":"12","author":"Metz","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"11","key":"10.1016\/j.jconrel.2021.09.020_bb0450","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2174\/1381612823666170913163904","article-title":"Development of peptide vaccines in dengue","volume":"24","author":"Reginald","year":"2018","journal-title":"Curr. Pharm. Des."},{"issue":"Pt 8","key":"10.1016\/j.jconrel.2021.09.020_bb0455","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1099\/vir.0.066084-0","article-title":"Delivery of antiviral small interfering RNA with gold nanoparticles inhibits dengue virus infection in vitro","volume":"95","author":"Paul","year":"2014","journal-title":"J. General Virol."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0460","series-title":"\"Nematode Infections:\" Infectious Disease Clinics of North America","author":"Knopp","year":"2012"},{"issue":"12","key":"10.1016\/j.jconrel.2021.09.020_bb0465","doi-asserted-by":"crossref","first-page":"e0207625","DOI":"10.1371\/journal.pone.0207625","article-title":"Chitosan-based nanodelivery systems applied to the development of novel triclabendazole formulations","volume":"13","author":"Real","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jconrel.2021.09.020_bb0470","first-page":"1","article-title":"Molluscicidal activities of curcumin-Nisin polylactic acid nanoparticle (PLA) on adult snail intermediate hosts of Schistosomes and Fasciola spp","volume":"1","author":"Omobhude","year":"2019","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0475","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.3389\/fimmu.2018.02253","article-title":"Salivarian trypanosomosis: a review of parasites involved, their global distribution and their interaction with the innate and adaptive mammalian host immune system","volume":"9","author":"Radwanska","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0480","series-title":"Nanotechnological Interventions for Treatment of Trypanosomiasis in Humans and Animals","first-page":"945","author":"Prayag","year":"2020"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0485","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jconrel.2014.11.002","article-title":"Nanobody conjugated PLGA nanoparticles for active targeting of African trypanosomiasis","volume":"197","author":"Arias","year":"2015","journal-title":"J. Control. Release"},{"issue":"10110","key":"10.1016\/j.jconrel.2021.09.020_bb0490","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/S0140-6736(17)31510-6","article-title":"Human african trypanosomiasis","volume":"390","author":"B\u00fcscher","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0495","first-page":"257","article-title":"Epidemiology of human African trypanosomiasis","volume":"6","author":"Franco","year":"2014","journal-title":"Clin. Epidemiol."},{"issue":"2","key":"10.1016\/j.jconrel.2021.09.020_bb0500","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0304-4017(03)00202-4","article-title":"Vaccination against cestode parasites: anti-helminth vaccines that work and why","volume":"115","author":"Lightowlers","year":"2003","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0505","series-title":"Amino acid transporters & amino acid metabolism in Trypanosoma brucei brucei","author":"Ebikeme","year":"2007"},{"issue":"2","key":"10.1016\/j.jconrel.2021.09.020_bb0510","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S1473-3099(19)30612-7","article-title":"New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice","volume":"20","author":"Lindner","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0515","first-page":"175","article-title":"Drug discovery and development for neglected diseases: the DNDi model","volume":"5","author":"Chatelain","year":"2011","journal-title":"Drug Design Develop. Therapy"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0520","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fnano.2021.665274","article-title":"Nano based approach for the treatment of neglected tropical diseases","volume":"3","author":"Pandian","year":"2021","journal-title":"Front. Nanotechnol."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0525","first-page":"257","article-title":"Epidemiology of human African trypanosomiasis","volume":"6","author":"Franco","year":"2014","journal-title":"Clin. Epidemiol."},{"issue":"2","key":"10.1016\/j.jconrel.2021.09.020_bb0530","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.ejpb.2008.05.012","article-title":"Comparison of nanosuspensions and hydroxypropyl-\u03b2-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice","volume":"70","author":"Zirar","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"6","key":"10.1016\/j.jconrel.2021.09.020_bb0535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004942","article-title":"Specific cell targeting therapy bypasses drug resistance mechanisms in African trypanosomiasis","volume":"11","author":"Unciti-Broceta","year":"2015","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.jconrel.2021.09.020_bb0540","article-title":"Evaluation of the hydatid cyst membrane permeability of albendazole and albendazole sulfoxide-loaded solid lipid nanoparticles","volume":"12","author":"Soltani","year":"2017","journal-title":"Jundish. J. Nat. Pharmac. Prod."},{"issue":"3","key":"10.1016\/j.jconrel.2021.09.020_bb0545","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3109\/21691401.2014.1000493","article-title":"Enhancing the bioavailability of mebendazole by integrating the principles solid dispersion and nanocrystal techniques, for safe and effective management of human echinococcosis","volume":"44","author":"Chaudhary","year":"2016","journal-title":"Artificial Cells Nanomed. Biotechnol."},{"issue":"4","key":"10.1016\/j.jconrel.2021.09.020_bb0550","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.parint.2009.07.006","article-title":"Flubendazole in cystic echinococcosis therapy: pharmaco-parasitological evaluation in mice","volume":"58","author":"Ceballos","year":"2009","journal-title":"Parasitol. Int."},{"issue":"12","key":"10.1016\/j.jconrel.2021.09.020_bb0555","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.1128\/AAC.05105-11","article-title":"Comparative performances of flubendazole and albendazole in cystic echinococcosis: ex vivo activity, plasma\/cyst disposition, and efficacy in infected mice","volume":"55","author":"Ceballos","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.jconrel.2021.09.020_bb0560","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/eri.11.30","article-title":"Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs","volume":"9","author":"Mackenzie","year":"2011","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0565","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.actatropica.2018.08.010","article-title":"Efficiency of flubendazole-loaded mPEG-PCL nanoparticles: a promising formulation against the protoscoleces and cysts of Echinococcus granulosus","volume":"187","author":"Farhadi","year":"2018","journal-title":"Acta Trop."},{"issue":"3","key":"10.1016\/j.jconrel.2021.09.020_bb0570","doi-asserted-by":"crossref","first-page":"148","DOI":"10.5152\/tpd.2011.37","article-title":"Effect of different concentrations of hypertonic saline at different times on protoscoleces of hydatid cyst isolated from liver and lung","volume":"35","author":"Tappeh","year":"2011","journal-title":"T\u00fcrk. Parazitol. Derg."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0575","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijsu.2015.05.043","article-title":"Scolicidal activity of biosynthesized silver nanoparticles against Echinococcus granulosus protoscolices","volume":"19","author":"Rahimi","year":"2015","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0580","series-title":"Nano Carrier Mediated Co-Delivery of Dapsone and Clofazimine for Improved Therapeutic Efficacy against Tuberculosis in Rats","author":"Li","year":"2017"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0585","first-page":"2601","article-title":"Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells","volume":"11","author":"Vieira","year":"2016","journal-title":"Int. J. Nanomedicine"},{"issue":"sup1","key":"10.1016\/j.jconrel.2021.09.020_bb0590","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/21691401.2018.1434186","article-title":"Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages","volume":"46","author":"Vieira","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"26","key":"10.1016\/j.jconrel.2021.09.020_bb0595","doi-asserted-by":"crossref","first-page":"6837","DOI":"10.1021\/acs.jpcb.8b03081","article-title":"Biomimetic solid lipid nanoparticles of sophorolipids designed for antileprosy drugs","volume":"122","author":"Kanwar","year":"2018","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0600","series-title":"Topical Delivery of Clofazimine from an Avocado Oil Nano-Emulsion","author":"Joubert","year":"2016"},{"issue":"10","key":"10.1016\/j.jconrel.2021.09.020_bb0605","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11095-018-2471-9","article-title":"Formulation of natural oil nano-emulsions for the topical delivery of clofazimine, artemisone and decoquinate","volume":"35","author":"Burger","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0610","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.biopha.2018.04.195","article-title":"Nanosystems as modulators of intestinal dapsone and clofazimine delivery","volume":"103","author":"Chaves","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0615","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.reffit.2016.10.007","article-title":"Effect of functionalization of polymeric nanoparticles incorporated with whole attenuated rabies virus antigen on sustained release and efficacy","volume":"2","author":"Nivedh","year":"2016","journal-title":"Resourc.-Efficient Technol."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0620","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.2147\/IJN.S109098","article-title":"Green synthesis and evaluation of silver nanoparticles as adjuvant in rabies veterinary vaccine","volume":"11","author":"Asgary","year":"2016","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0625","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/vim.2017.0024","article-title":"Evaluation of G2 citric acid-based dendrimer as an adjuvant in veterinary rabies vaccine","volume":"31","author":"Asgary","year":"2018","journal-title":"Viral Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0630","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.actatropica.2013.06.011","article-title":"Liposomal-praziquantel: efficacy against Schistosoma mansoni in a preclinical assay","volume":"128","author":"Frezza","year":"2013","journal-title":"Acta Trop."},{"issue":"3","key":"10.1016\/j.jconrel.2021.09.020_bb0635","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s40995-017-0150-z","article-title":"Albendazole and praziquantel chitosan nanoparticles: preparation, characterization, and in vitro release study","volume":"42","author":"Torabi","year":"2018","journal-title":"Iran. J. Sci. Technol. Trans. A: Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0640","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijpharm.2013.12.022","article-title":"In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment","volume":"463","author":"de Souza","year":"2014","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0645","doi-asserted-by":"crossref","first-page":"68","DOI":"10.34172\/apb.2021.004","article-title":"A novel treatment of schistosomiasis: nano-calcium silicate incorporating 5% copper oxide","volume":"11","author":"Abou El-Nour","year":"2021","journal-title":"Adv. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.jconrel.2021.09.020_bb0650","doi-asserted-by":"crossref","first-page":"363","DOI":"10.12816\/0050443","article-title":"In vitro effects of iron nanoparticles on Schistosoma mansoni adult worms and its intermediate host snail, Biomphalaria alexandrina","volume":"48","author":"Khalil","year":"2018","journal-title":"J. Egypt. Soc. Parasitol."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0655","first-page":"593","article-title":"Vanderlei Rodrigues & Marcio","volume":"110","author":"Silva","year":"2012","journal-title":"Parasitol. Res."},{"issue":"5","key":"10.1016\/j.jconrel.2021.09.020_bb0660","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bmc.2017.01.034","article-title":"Carbonic anhydrases from Trypanosoma and Leishmania as anti-protozoan drug targets","volume":"25","author":"Vermelho","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0665","doi-asserted-by":"crossref","first-page":"750","DOI":"10.12688\/f1000research.11120.1","volume":"6","author":"Torres-Guerrero","year":"2017","journal-title":"F1000Research"},{"issue":"4","key":"10.1016\/j.jconrel.2021.09.020_bb0670","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-004709","article-title":"Neglected tropical diseases as a barometer for progress in health systems in times of COVID-19","volume":"6","author":"Ehrenberg","year":"2021","journal-title":"BMJ Glob. Health"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0675","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s42485-020-00035-w","article-title":"Review on natural products as an alternative to contemporary anti-leishmanial therapeutics","volume":"11","author":"Raj","year":"2020","journal-title":"J. Proteins Proteomics."},{"issue":"4","key":"10.1016\/j.jconrel.2021.09.020_bb0680","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3390\/nano10040656","article-title":"Systemic review of biodegradable nanomaterials in nanomedicine","volume":"10","author":"Su","year":"2020","journal-title":"Nanomaterials."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0685","series-title":"Pharmaceutical Studies of Amphotericin-B: $$ b Oral Formulation using Nanotechnology (Doctoral dissertation)","author":"AL Quadeib","year":"2021"},{"issue":"2","key":"10.1016\/j.jconrel.2021.09.020_bb0690","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00436-019-06575-5","article-title":"Environmental and socioeconomic risk factors associated with visceral and cutaneous leishmaniasis: a systematic review","volume":"119","author":"Valero","year":"2020","journal-title":"Parasitol. Res."},{"issue":"3","key":"10.1016\/j.jconrel.2021.09.020_bb0695","first-page":"269","article-title":"Safety evaluation of nano-liposomal formulation of amphotericin B (sina ampholeish) in animal model as a candidate for treatment of cutaneous leishmaniasis","volume":"12","author":"Eskandari","year":"2018","journal-title":"J. Arthropod. Borne Dis."},{"issue":"5","key":"10.1016\/j.jconrel.2021.09.020_bb0700","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1021\/acsbiomaterials.0c01132","article-title":"Nano-and microformulations to advance therapies for visceral Leishmaniasis","volume":"7","author":"Varma","year":"2020","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0705","doi-asserted-by":"crossref","first-page":"110712","DOI":"10.1016\/j.nut.2019.110712","article-title":"Nutrition, malnutrition, and leishmaniasis","volume":"73","author":"Nweze","year":"2020","journal-title":"Nutrition."},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0710","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actatropica.2007.08.003","article-title":"Mucosal leishmaniasis: current scenario and prospects for treatment","volume":"105","author":"Amato","year":"2008","journal-title":"Acta Trop."},{"issue":"3","key":"10.1016\/j.jconrel.2021.09.020_bb0715","article-title":"Leishmaniasis research in India: a scientometric assessment of publications during 2008\u201317","volume":"8","author":"Ahmed","year":"2018","journal-title":"Int. J. Med. Public Health"},{"issue":"6","key":"10.1016\/j.jconrel.2021.09.020_bb0720","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.3390\/nano10061152","article-title":"Amphotericin B loaded polymeric nanoparticles for treatment of leishmania infections","volume":"10","author":"Saqib","year":"2020","journal-title":"Nanomaterials."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0725","doi-asserted-by":"crossref","first-page":"7593","DOI":"10.2147\/IJN.S220410","article-title":"Comparative analysis between four model nanoformulations of amphotericin B-chitosan, amphotericin B-dendrimer, betulinic acid-chitosan and betulinic acid-dendrimer for treatment of Leishmania major: Real-time PCR assay plus","volume":"14","author":"Mehrizi","year":"2019","journal-title":"Int. J. Nanomedicine"},{"issue":"17","key":"10.1016\/j.jconrel.2021.09.020_bb0730","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.3390\/molecules25174002","article-title":"Activity of amphotericin B-loaded chitosan nanoparticles against experimental cutaneous leishmaniasis","volume":"25","author":"Riezk","year":"2020","journal-title":"Molecules."},{"issue":"9","key":"10.1016\/j.jconrel.2021.09.020_bb0735","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/pharmaceutics12090858","article-title":"Berberine-loaded liposomes for the treatment of leishmania infantum-infected balb\/c mice","volume":"12","author":"Calvo","year":"2020","journal-title":"Pharmaceutics."},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0740","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-69276-5","article-title":"Modified solid lipid nanoparticles encapsulated with amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis","volume":"10","author":"Parvez","year":"2020","journal-title":"Sci. Rep."},{"issue":"sup1","key":"10.1016\/j.jconrel.2021.09.020_bb0745","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1080\/21691401.2018.1430699","article-title":"Design of mannosylated oral amphotericin B nanoformulation: efficacy and safety in visceral leishmaniasis","volume":"46","author":"Sarwar","year":"2018","journal-title":"Artificial Cells Nanomed. Biotechnol."},{"issue":"15","key":"10.1016\/j.jconrel.2021.09.020_bb0750","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.4155\/fmc.13.143","article-title":"Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives","volume":"5","author":"Yasinzai","year":"2013","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0755","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.carbpol.2013.10.044","article-title":"Mannose-conjugated chitosan nanoparticles loaded with rifampicin for the treatment of visceral leishmaniasis","volume":"101","author":"Chaubey","year":"2014","journal-title":"Carbohydr. Polym."},{"issue":"5","key":"10.1016\/j.jconrel.2021.09.020_bb0760","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008314","article-title":"Significant improvement in quality of life following surgery for hydrocoele caused by lymphatic filariasis in Malawi: a prospective cohort study","volume":"14","author":"Betts","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"3","key":"10.1016\/j.jconrel.2021.09.020_bb0765","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/02726351.2020.1750515","article-title":"Development of mebendazole loaded nanostructured lipid carriers for lymphatic targeting: optimization, characterization, in-vitro and in-vivo evaluation","volume":"39","author":"Shrivastava","year":"2021","journal-title":"Part. Sci. Technol."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0770","series-title":"Pharmaceutics","article-title":"Enhanced Intradermal Delivery of Nanosuspensions of Antifilariasis Drugs Using Dissolving Microneedles: A Proof of Concept Study","author":"Permana","year":"2019"},{"issue":"2","key":"10.1016\/j.jconrel.2021.09.020_bb0775","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00436-013-3696-5","article-title":"Therapeutic efficacy of poly (lactic-co-glycolic acid) nanoparticles encapsulated ivermectin (nano-ivermectin) against brugian filariasis in experimental rodent model","volume":"113","author":"Ali","year":"2014","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0780","first-page":"105677","article-title":"Onchocerciasis (river blindness)\u2013more than a century of research and control","volume":"26","author":"Brattig","year":"2020","journal-title":"Acta Trop."},{"issue":"11","key":"10.1016\/j.jconrel.2021.09.020_bb0785","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1473-3099(20)30122-5","article-title":"Changes in epilepsy burden after onchocerciasis elimination in a hyperendemic focus of western Uganda: a comparison of two population-based, cross-sectional studies","volume":"20","author":"Gumisiriza","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0790","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-66012-x","article-title":"A treponemal genome from an historic plague victim supports a recent emergence of yaws and its presence in 15 th century Europe","volume":"10","author":"Giffin","year":"2020","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.jconrel.2021.09.020_bb0795","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/S2666-5247(20)30113-0","article-title":"Yaws re-emergence and bacterial drug resistance selection after mass administration of azithromycin: a genomic epidemiology investigation","volume":"1","author":"Beale","year":"2020","journal-title":"Lancet Microbe."},{"issue":"5","key":"10.1016\/j.jconrel.2021.09.020_bb0800","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008226","article-title":"Ocular Chlamydia trachomatis infection and infectious load among pre-school aged children within trachoma hyperendemic districts receiving the SAFE strategy, Amhara region, Ethiopia","volume":"14","author":"Nash","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"9","key":"10.1016\/j.jconrel.2021.09.020_bb0805","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008316","article-title":"The use of serology for trachoma surveillance: current status and priorities for future investigation","volume":"14","author":"Martin","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2021.09.020_bb0810","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijpharm.2017.05.045","article-title":"Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection","volume":"527","author":"Ganda","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.jconrel.2021.09.020_bb0815","doi-asserted-by":"crossref","DOI":"10.5812\/jjnpp.13938","article-title":"A novel microemulsion system for ocular delivery of azithromycin: Design, characterization and ex-vivo rabbit corneal permeability","volume":"12","author":"Salimi","year":"2017","journal-title":"Jundishapur J. Nat. Pharm. Prod"},{"issue":"5","key":"10.1016\/j.jconrel.2021.09.020_bb0820","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006391","article-title":"A holistic approach to the mycetoma management","volume":"12","author":"Bakhiet","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0825","doi-asserted-by":"crossref","DOI":"10.1111\/ajd.13592","article-title":"First report of cutaneous mycetoma by Paecilomyces variotii and the successful treatment with combined itraconazole and terbinafine along with resection surgeries","author":"Criado","year":"2021","journal-title":"Australasian Journal of Dermatology"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0830","first-page":"1","article-title":"Linezolid: a novel treatment option for the treatment of a non-responsive case of actinomycotic mycetoma","author":"Patra","year":"2021","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0835","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1128\/CMR.00032-16","article-title":"Chromoblastomycosis","volume":"30","author":"Queiroz-Telles","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"issue":"4","key":"10.1016\/j.jconrel.2021.09.020_bb0840","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1590\/abd1806-4841.20187321","article-title":"Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update","volume":"93","author":"Brito","year":"2018","journal-title":"An. Bras. Dermatol."},{"issue":"8","key":"10.1016\/j.jconrel.2021.09.020_bb0845","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/jdv.14351","article-title":"European guideline for the management of scabies","volume":"31","author":"Salavastru","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0850","article-title":"Ivermectin and permethrin for treating scabies","volume":"4","author":"Rosumeck","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.jconrel.2021.09.020_bb0855","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1248\/cpb.c17-00965","article-title":"Design of a topically applied gel spray formulation with ivermectin using a novel low molecular weight gelling agent, palmitoyl-glycine-histidine, to treat scabies","volume":"66","author":"Dahlizar","year":"2018","journal-title":"Chem. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.jconrel.2021.09.020_bb0860","first-page":"1","article-title":"Snakebite envenoming","volume":"3","author":"Guti\u00e9rrez","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0865","series-title":"Snakebite Envenoming: A Strategy for Prevention and Control","author":"World Health Organization","year":"2019"},{"key":"10.1016\/j.jconrel.2021.09.020_bb0870","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biologicals.2021.01.003","article-title":"Development and evaluation of polymeric nanoparticles as a delivery system for snake envenoming prevention","volume":"70","author":"Hamzaoui","year":"2021","journal-title":"Biologicals."},{"key":"10.1016\/j.jconrel.2021.09.020_bb0875","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.ijbiomac.2018.09.203","article-title":"A biotechnological approach to immunotherapy: Antivenom against Crotalus durissus cascavella snake venom produced from biodegradable nanoparticles","volume":"120","author":"Gl\u00e1ucia-Silva","year":"2018","journal-title":"Int. J. Biol. Macromol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921004995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365921004995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:21:23Z","timestamp":1778300483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365921004995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":175,"alternative-id":["S0168365921004995"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.09.020","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Road map to the treatment of neglected tropical diseases: Nanocarriers interventions","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2021.09.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}